Wall Street brokerages expect Pluristem Therapeutics Inc. (NASDAQ:PSTI) to post earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics posted earnings per share of ($0.09) in the same quarter last year, which indicates a positive year over year growth rate of 22.2%. The business is expected to issue its next quarterly earnings report on Monday, May 8th.
According to Zacks, analysts expect that Pluristem Therapeutics will report full year earnings of ($0.32) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.30). For the next financial year, analysts forecast that the business will report earnings of ($0.01) per share, with EPS estimates ranging from ($0.33) to $0.32. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Pluristem Therapeutics.
A number of research firms recently commented on PSTI. Zacks Investment Research downgraded Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 3rd. HC Wainwright set a $4.00 target price on Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Saturday, February 11th. Maxim Group set a $3.00 target price on Pluristem Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, January 17th. Finally, FBR & Co reaffirmed an “outperform” rating and set a $6.00 target price on shares of Pluristem Therapeutics in a research report on Friday, December 23rd.
An institutional investor recently raised its position in Pluristem Therapeutics stock. Oppenheimer & Co. Inc. increased its position in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 23.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 127,000 shares of the biotechnology company’s stock after buying an additional 24,000 shares during the period. Oppenheimer & Co. Inc. owned approximately 0.16% of Pluristem Therapeutics worth $203,000 as of its most recent SEC filing. 3.05% of the stock is currently owned by institutional investors.
Pluristem Therapeutics (NASDAQ:PSTI) traded down 1.44% during midday trading on Monday, hitting $1.37. 112,603 shares of the company traded hands. The company’s market cap is $131.61 million. The stock has a 50 day moving average price of $1.27 and a 200-day moving average price of $1.38. Pluristem Therapeutics has a 12-month low of $1.04 and a 12-month high of $1.85.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.